Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Centrre Hospitalier National D'Ophtalmologie Quinze-Vingts currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is managed by 1 distinct examiner and is located within 1 distinct art unit. The presence of 1 distinct examiner indicates that the company's current applications are being reviewed by a specific official. This concentration simplifies the coordination of prosecution strategies.
The busiest examiner for the portfolio is PENNINGTON, KATIE LEIGH, who is responsible for 1 busiest examiner pending action. This 1 busiest examiner pending action is the matter currently under review. The 1 distinct art unit provides the specific technical context for the examination. Practitioners should focus on the tendencies of the 1 distinct examiner within the 1 distinct art unit. The Biotechnology & Pharmaceuticals technology area is the primary field for the 1 pending office action, which represents the company's current active workload.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17995880 | G-PROTEIN-GATED-K+ CHANNEL-MEDIATED ENHANCEMENTS IN LIGHT SENSITIVITY IN ROD-CONE DYSTROPHY (RCD) | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17995880 | G-PROTEIN-GATED-K+ CHANNEL-MEDIATED ENHANCEMENTS IN LIGHT SENSITIVITY IN ROD-CONE DYSTROPHY (RCD) | PENNINGTON, KATIE LEIGH | 1634 | §103 | Final Rejection | — | Pending | Oct 10, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCentrre Hospitalier National D'Ophtalmologie Quinze-Vingts has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katie Leigh Pennington has the most, with 1 of Centrre Hospitalier National D'Ophtalmologie Quinze-Vingts's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
